Aditxt (ADTX) Competitors $1.16 -0.08 (-6.10%) As of 03:46 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ADTX vs. SNSE, CSCI, PHXM, NLSP, BCDA, GLYC, ADXN, LSB, TLPH, and APREShould you be buying Aditxt stock or one of its competitors? The main competitors of Aditxt include Sensei Biotherapeutics (SNSE), COSCIENS Biopharma (CSCI), PHAXIAM Therapeutics (PHXM), NLS Pharmaceutics (NLSP), BioCardia (BCDA), GlycoMimetics (GLYC), Addex Therapeutics (ADXN), LakeShore Biopharma (LSB), Talphera (TLPH), and Aprea Therapeutics (APRE). These companies are all part of the "pharmaceutical products" industry. Aditxt vs. Its Competitors Sensei Biotherapeutics COSCIENS Biopharma PHAXIAM Therapeutics NLS Pharmaceutics BioCardia GlycoMimetics Addex Therapeutics LakeShore Biopharma Talphera Aprea Therapeutics Sensei Biotherapeutics (NASDAQ:SNSE) and Aditxt (NASDAQ:ADTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings, risk and media sentiment. Which has more risk and volatility, SNSE or ADTX? Sensei Biotherapeutics has a beta of 0.27, suggesting that its stock price is 73% less volatile than the S&P 500. Comparatively, Aditxt has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500. Is SNSE or ADTX more profitable? Sensei Biotherapeutics has a net margin of 0.00% compared to Aditxt's net margin of -46,082.47%. Sensei Biotherapeutics' return on equity of -66.72% beat Aditxt's return on equity.Company Net Margins Return on Equity Return on Assets Sensei BiotherapeuticsN/A -66.72% -57.10% Aditxt -46,082.47%-389.10%-84.71% Do analysts recommend SNSE or ADTX? Sensei Biotherapeutics currently has a consensus price target of $90.00, suggesting a potential upside of 922.73%. Given Sensei Biotherapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Sensei Biotherapeutics is more favorable than Aditxt.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sensei Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Aditxt 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals & insiders have more ownership in SNSE or ADTX? 10.5% of Sensei Biotherapeutics shares are owned by institutional investors. Comparatively, 15.5% of Aditxt shares are owned by institutional investors. 23.2% of Sensei Biotherapeutics shares are owned by insiders. Comparatively, 0.0% of Aditxt shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media favor SNSE or ADTX? In the previous week, Aditxt had 3 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 3 mentions for Aditxt and 0 mentions for Sensei Biotherapeutics. Aditxt's average media sentiment score of 0.86 beat Sensei Biotherapeutics' score of 0.00 indicating that Aditxt is being referred to more favorably in the news media. Company Overall Sentiment Sensei Biotherapeutics Neutral Aditxt Positive Which has preferable valuation & earnings, SNSE or ADTX? Sensei Biotherapeutics has higher earnings, but lower revenue than Aditxt. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSensei BiotherapeuticsN/AN/A-$30.16M-$23.00-0.38Aditxt$130K18.84-$34.45MN/AN/A SummarySensei Biotherapeutics beats Aditxt on 9 of the 14 factors compared between the two stocks. Get Aditxt News Delivered to You Automatically Sign up to receive the latest news and ratings for ADTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADTX vs. The Competition Export to ExcelMetricAditxtMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.45M$2.37B$5.44B$8.92BDividend YieldN/A1.78%5.22%4.00%P/E RatioN/A8.8927.2520.05Price / Sales18.84666.36426.50117.27Price / CashN/A21.7726.2128.59Price / Book-0.764.507.925.57Net Income-$34.45M$31.26M$3.17B$248.56M7 Day Performance-9.77%5.60%4.48%7.44%1 Month Performance-25.00%5.93%2.80%8.43%1 Year Performance-99.99%8.83%35.04%21.72% Aditxt Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADTXAditxtN/A$1.16-6.1%N/A-100.0%$2.45M$130K0.0060High Trading VolumeSNSESensei Biotherapeutics4.1746 of 5 stars$8.58-1.2%$90.00+949.0%-27.1%$10.81MN/A-0.3740CSCICOSCIENS BiopharmaN/A$3.40+1.8%N/AN/A$10.71M$9.59M-0.5920Gap DownPHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58M$32.66M0.0049NLSPNLS PharmaceuticsN/A$2.90+3.9%N/A+1,191.0%$10.44MN/A0.006News CoverageAnalyst UpgradeBCDABioCardia3.9753 of 5 stars$1.95-9.3%$25.00+1,182.1%-29.0%$10.10M$60K-0.8440Positive NewsGLYCGlycoMimetics1.1504 of 5 stars$0.16-6.6%N/A-99.4%$10.00M$10K-0.3450High Trading VolumeADXNAddex Therapeutics2.5406 of 5 stars$9.41+4.6%$30.00+218.8%+7.0%$9.98M$460K-27.6830LSBLakeShore Biopharma0.3421 of 5 stars$1.02+11.0%N/AN/A$9.50M$80.82M0.00773Positive NewsGap UpHigh Trading VolumeTLPHTalphera1.9603 of 5 stars$0.46-1.7%$5.00+986.5%-50.5%$9.43M$650K-1.0219Gap UpAPREAprea Therapeutics2.5085 of 5 stars$1.69+0.9%$15.50+817.2%-54.9%$9.35M$1.50M-0.717 Related Companies and Tools Related Companies Sensei Biotherapeutics Alternatives COSCIENS Biopharma Alternatives PHAXIAM Therapeutics Alternatives NLS Pharmaceutics Alternatives BioCardia Alternatives GlycoMimetics Alternatives Addex Therapeutics Alternatives LakeShore Biopharma Alternatives Talphera Alternatives Aprea Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADTX) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aditxt, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aditxt With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
